You are here

  • Home
  • Archive
  • Volume 28, Issue 4
  • Safety and Efficacy of Extended Bevacizumab Therapy in Elderly (≥70 Years) Versus Younger Patients Treated for Newly Diagnosed Ovarian Cancer in the International ROSiA Study

Article info

Article menu

Download PDFPDF

Ovarian Cancer
Safety and Efficacy of Extended Bevacizumab Therapy in Elderly (≥70 Years) Versus Younger Patients Treated for Newly Diagnosed Ovarian Cancer in the International ROSiA Study

Authors

  1. Address correspondence and reprint requests to Frédéric Selle, MD, Service d'Oncologie Médicale, Groupe Hospitalier Diaconesses Croix Saint Simon and Alliance Pour la Recherche en Cancérologie, 125 rue d'Avron, 75020 Paris, France. E-mail: Fselle{at}hopital-dcss.org.

Citation

Selle F, Colombo N, Korach J, et al
Safety and Efficacy of Extended Bevacizumab Therapy in Elderly (≥70 Years) Versus Younger Patients Treated for Newly Diagnosed Ovarian Cancer in the International ROSiA Study
International Journal of Gynecologic Cancer 2018;28:729-737.

Publication history

  • Received August 6, 2017
  • Accepted December 27, 2017
  • First published May 1, 2018.
Online issue publication 
January 27, 2021

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© 2018 by the International Gynecologic Cancer Society and the European Society of Gynaecological Oncology.